$45.41
Price
$26.3B
Market Cap
25.5
P/E Ratio
8.4
Forward P/E
$1.78
EPS (TTM)
2.07%
Dividend Yield
$637M
Cash
$9.0B
Total Debt
428M
Shares Out
$29.66
$46.10
52-Week Range
Institutional Ownership of ROYALTY PHARMA PLC
|
Fund / Manager
Click to search
|
Shares | Value | % of Portfolio | Cost Basis | Est. Return |
|---|---|---|---|---|---|
|
Patient Capital Management|Samantha McLemore
|
3.3M | $129M | $27.85 | +44.04% | |
|
Dorsey Asset Management|Pat Dorsey
|
2.3M | $87M | $36.17 | +10.89% |
Trading Activity for ROYALTY PHARMA PLC
|
Fund / Manager
Click to search
|
Action | Change | Shares After | Value | Price |
|---|---|---|---|---|---|
| 2025-Q4 | |||||
| BUY | +6.9% | 3.3M | $129M | $38.43 | |
| SELL | -3.9% | 2.3M | $87M | $38.43 | |
| 2025-Q3 | |||||
| BUY | +4.3% | 3.1M | $110M | $36.17 | |
| SELL | EXIT | — | — | $36.17 | |
| BUY | NEW | 2.4M | $83M | $36.17 | |
| BUY | +2.0% | 702.9K | $25M | $36.17 | |
| 2025-Q2 | |||||
| SELL | -75.4% | 2.6M | $94M | $32.82 | |
| BUY | +0.5% | 3.0M | $108M | $32.82 | |
| SELL | -20.1% | 688.8K | $25M | $32.82 | |
| 2025-Q1 | |||||
| SELL | -13.5% | 10.6M | $329M | $32.25 | |
| BUY | +3.4% | 3.0M | $93M | $32.25 | |
| BUY | +26.0% | 862.0K | $27M | $32.25 | |
| 2024-Q4 | |||||
| BUY | +0.9% | 12.2M | $311M | $26.43 | |
| BUY | +40.9% | 2.9M | $73M | $26.43 | |
| SELL | -20.3% | 684.0K | $17M | $26.43 | |
| 2024-Q3 | |||||
| BUY | +1.0% | 12.1M | $342M | $27.78 | |
| BUY | +43.3% | 2.0M | $58M | $27.78 | |
| BUY | +23.7% | 857.9K | $24M | $27.78 | |
| 2024-Q2 | |||||
| BUY | +4.2% | 12.0M | $316M | $27.70 | |
| BUY | +0.3% | 1.4M | $38M | $27.70 | |
| BUY | +3.5% | 693.6K | $18M | $27.70 | |
| 2024-Q1 | |||||
| BUY | +13.9% | 11.5M | $349M | $29.43 | |
| BUY | +13.2% | 1.4M | $43M | $29.43 | |
| BUY | +32.5% | 670.1K | $20M | $29.43 | |
| 2023-Q4 | |||||
| BUY | +6.6% | 10.1M | $283M | $27.35 | |
| BUY | NEW | 1.3M | $35M | $27.35 | |
| BUY | +22.6% | 505.7K | $14M | $27.35 | |
| 2023-Q3 | |||||
| SELL | -3.9% | 9.5M | $257M | $30.21 | |
| SELL | -0.3% | 412.6K | $11M | $30.21 | |
| 2023-Q2 | |||||
| SELL | -12.1% | 9.9M | $303M | $33.86 | |
| BUY | +201.7% | 413.8K | $13M | $33.86 | |
| 2023-Q1 | |||||
| BUY | +11.9% | 11.2M | $404M | $37.84 | |
| SELL | -0.1% | 137.2K | $5M | $37.84 | |
| 2022-Q4 | |||||
| SELL | -8.0% | 10.0M | $396M | $41.94 | |
| SELL | -1.2% | 137.4K | $5M | $41.94 | |
| 2022-Q3 | |||||
| SELL | -12.0% | 10.9M | $437M | $42.96 | |
| BUY | +0.0% | 139.0K | $6M | $42.96 | |
| 2022-Q2 | |||||
| BUY | +198.8% | 12.4M | $520M | $40.77 | |
| SELL | EXIT | — | — | $40.77 | |
| BUY | +5.3% | 139.0K | $6M | $40.77 | |
| 2022-Q1 | |||||
| SELL | -59.9% | 4.1M | $150M | $39.14 | |
| SELL | -82.7% | 1.5M | $58M | $39.14 | |
| SELL | -4.3% | 132.1K | $5M | $39.14 | |
| 2021-Q4 | |||||
| SELL | -34.2% | 8.6M | $345M | $38.55 | |
| BUY | +149.1% | 10.3M | $411M | $38.55 | |
| BUY | NEW | 137.9K | $5M | $38.55 | |
| 2021-Q3 | |||||
| BUY | NEW | 13.1M | $475M | $38.73 | |
| BUY | +27.9% | 4.1M | $150M | $38.73 | |
| 2021-Q2 | |||||
| BUY | +57.1% | 3.2M | $133M | $42.25 | |
| 2021-Q1 | |||||
| SELL | -9.8% | 2.1M | $90M | $47.20 | |
| 2020-Q4 | |||||
| BUY | +17.4% | 2.3M | $114M | $42.29 | |
| 2020-Q3 | |||||
| SELL | -22.5% | 1.9M | $82M | $42.78 | |
| 2020-Q2 | |||||
| BUY | NEW | 2.5M | $122M | $49.92 | |
Insider Trading for ROYALTY PHARMA PLC
No Insider Transactions
No Form 4 filings found for this stock in the last 2 years.